Loading stock data…
$10.53-0.12 (-1.13%)
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Corvus Pharmaceuticals, Inc. in the Healthcare sector is trading at $10.53 with a market capitalization of $1.3B. Wall Street consensus targets $33.14 (7 analysts), implying a +214.7% move over the next 12 months. The stock is currently 61% below its 52-week high of $26.95, remaining 26.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.30M↓ | -$14.88M↓ | -$12.22M↓ | -$10.57M↓ | -$10.26M |
| Net Income | -$17.96M↓ | -$13.69M↓ | -$12.32M↓ | -$10.16M↓ | -$8.00M |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lea...